$XBI $128 -1%
Covid Updates
$MRNA -6% Initial data from ph 2 booster study in covid variants. source
$CYDY -5% Partner with ARO in Brazil for 2 Covid trials, critically-ill and severe patients. source
Pipeline Updates
$ZYNE +3% Received guidance from FDA for pivotal ph 3 trial of Zygel in Fragile X Syndrome, initiation planned for Q3 '21. source
$CBIO -2% Enrolled first patient in pivotal ph 3 trial (Crimson-01) of MarzAA for Hem A/B. source
$REPL +9% Update to ph 2 RP1 + Opdivo, CR as a PE, and target enrollment 180 patients. source
Financial Updates
$CRVS +6% Sold $10 shares through ATM program to EcoR1 Capital and CEO. source
$AMYT -7% to acquire $CHMA +44% source
$TLSA 0% Agreement with Takanawa to find partner in Japan and Asia for Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients. source